RPG Life Sciences Ltd - 532983 - Announcement under Regulation 30 (LODR)-Acquisition
RPG Life Sciences' wholly-owned subsidiary, RPG Active Pharma Limited, acquired a 100% stake in Actis Generics Private Limited for Rs. 80 crore. This acquisition aligns with the company's strategy to expand its Active Pharmaceutical Ingredients (API) business.
Jul 29 2026 23:45:02
RPG Life Sciences Ltd - 532983 - Announcement under Regulation 30 (LODR)-Restructuring
RPG Life Sciences Board approved a multi-faceted restructuring of its API business. The API division will be sold to its WOS, RPG Active Pharma Ltd. (RPGAP). RPGAP will raise Rs.243.33 crore from India Life Sciences Fund IV and Vistaject Fund, and acquire Actis Generics for Rs.80 crore.
Jul 29 2026 23:40:53
RPG Life Sciences Ltd - 532983 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
RPG Life Sciences issued a press release detailing its Q1 FY27 financial results. The company reported a 15.8% increase in revenue to ₹195.7 crore and a 17.9% growth in EBITDA to ₹48.0 crore, with an EBITDA margin of 24.5% driven by operating discipline and market outperformance.
Jul 28 2026 20:11:24
RPG Life Sciences Ltd - 532983 - Board Meeting Outcome for Outcome Of Board Meeting
RPG Life Sciences' board approved Q1 FY27 consolidated financial results on July 28, 2026. Revenue from operations increased 15.85% YoY to ₹195.69 crores, while net profit grew 17.00% YoY to ₹30.76 crores, reflecting strong operational performance.
Jul 28 2026 19:53:42
RPG Life Sciences Ltd - 532983 - Board Meeting Intimation for Financial Result For Quarter Ended June 2026
RPG Life Sciences has scheduled a board meeting for July 28, 2026. The board will consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.
Jul 21 2026 19:06:29
RPG Life Sciences Ltd - 532983 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
RPG Life Sciences has partnered with Archerchem Healthcare to launch Naprosyn ES in India. This first-in-India combination of Naproxen and Esomeprazole will be exclusively marketed and distributed by RPG LS, enhancing its chronic therapy portfolio.
Jul 13 2026 12:36:54
Read More